Paliperidone Palmitate Injection（Ⅱ） (Luye Pharma)

Tier C — Watch / trade

Originator

2024

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：5-HT2A, DRD2

Brand：ERZOFRI

Indications (approved)：Schizophrenia, 情感分裂性精神障碍

Regional status

Approved

2024-07-26

China

Approved

2025-06-24

Japan

Factories producing this API1

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

1 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Paliperidone Palmitate Injection（Ⅱ） (Luye Pharma)?

Approved indications include: Schizophrenia, 情感分裂性精神障碍.

When does the Paliperidone Palmitate Injection（Ⅱ） (Luye Pharma) patent expire?

No public expiry year is available for Paliperidone Palmitate Injection（Ⅱ） (Luye Pharma) yet; this page updates once verified.

How do I get a quote for Paliperidone Palmitate Injection（Ⅱ） (Luye Pharma) intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27